Cytocentric-Blog

cytocentric visionaries mg p1Cytocentric Visionaries: Michael Gilkey, CEO Trailhead Biosystems

Part One: Optimizing Cell Media in 12 Dimensions: You Can’t Do This by Hand

Alicia Henn, Chief Scientific Officer, BioSpherix

In addition to being CEO of the Ohio start-up Trailhead Biosystems, Michael Gilkey is the Director of Strategic Partnerships for the National Center for Regenerative Medicine. Michael and his team have established a unique platform for Design of Experiments Theory-based cell differentiation optimization. Trailhead uses an Xvivo barrier isolator system from BioSpherix to protect the cells from room air and maintain physiologic oxygen levels

Here, Alicia talks with Michael about using a 12-dimension hypercube of variables, robotics, and mathematical modeling to quickly identify the best combinations of components for media used in cellular therapeutics. This conversation with Dr. Michael Gilkey to discuss optimizing cell therapy media with physiologic conditions was edited for length.

cytocentric visionaries dp p3Cytocentric Visionaries: Donald Phinney

Part 3: The Cell Cycle Is the Redox Cycle, and All Clinical MSC are Stressed

In Part Two, Chief Scientific Officer Alicia Henn talked with Dr. Phinney about MSC, the exosomes that they produce and therapeutics. Today we talk about MSC and oxidative stress in vitro. This conversation on the importance of studying the cellular redox balance in MSC cells was edited for length.

cytocentric visionaries dp p2Cytocentric Visionaries: Donald Phinney

Part Two: MSC vs Exosomes and Therapies

In Part One, Chief Scientific Officer Alicia Henn talks with Dr. Phinney about his publication in Nature Communications, ”Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs”[Phinney et al., 2015]. Here we continue that conversation and discuss why exosomes have an advantage over MSC cells (interview edited for length).

cytocentric visionaries dp p1Cytocentric Visionaries: Donald Phinney, Chair Department of Molecular Therapeutics, The Scripps Research Institute

Part One: Mesenchymal Stem Cells, as Healers, Aren’t So Selfless

Chair of the Molecular Therapeutics Department at Scripps, Dr. Phinney has almost 20 years of experience in the adult stem cell field and has been an editor of prominent stem cell journals. Here, Alicia Henn talks with Dr. Phinney about his latest publication in Nature Communications, ”Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs”[Phinney et al., 2015]. This conversation on understanding how MSC stem cells affect macrophage biology was edited for length.

Phinney and his co-authors reported that in response to oxidative stress, MSCs export damaged mitochondria to nearby macrophages, which recycle them for their own bioenergetics. The MSCs also export exosomes containing miRNAs that reduce the inflammatory activities of macrophage through TLR-7 signaling pathways. This benefits the nearby MSCs, and is also a mechanism by which MSCs may have their clinical effects on surrounding tissues.

Gas Control in Semi-sealed Chambers

Dalton in the Incubator

bp035 c21 CchamberWe are all familiar with how CO2 is infused into cell culture incubators to raise CO2 to physiologic levels and keep carbonic acid based media in the proper pH range for cells. However, managing a system for a gas infusion system necessitates understanding how mixed gases work in a semi-sealed cell incubator chamber.